JP2016535758A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535758A5
JP2016535758A5 JP2016534884A JP2016534884A JP2016535758A5 JP 2016535758 A5 JP2016535758 A5 JP 2016535758A5 JP 2016534884 A JP2016534884 A JP 2016534884A JP 2016534884 A JP2016534884 A JP 2016534884A JP 2016535758 A5 JP2016535758 A5 JP 2016535758A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
conh
haloalkyl
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534884A
Other languages
English (en)
Japanese (ja)
Other versions
JP6458270B2 (ja
JP2016535758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/051459 external-priority patent/WO2015024010A2/en
Publication of JP2016535758A publication Critical patent/JP2016535758A/ja
Publication of JP2016535758A5 publication Critical patent/JP2016535758A5/ja
Application granted granted Critical
Publication of JP6458270B2 publication Critical patent/JP6458270B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534884A 2013-08-16 2014-08-18 置換されたヒドロキサム酸化合物 Expired - Fee Related JP6458270B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361866823P 2013-08-16 2013-08-16
US61/866,823 2013-08-16
US201361867933P 2013-08-20 2013-08-20
US61/867,933 2013-08-20
PCT/US2014/051459 WO2015024010A2 (en) 2013-08-16 2014-08-18 Substituted hydroxamic acid compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018224004A Division JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Publications (3)

Publication Number Publication Date
JP2016535758A JP2016535758A (ja) 2016-11-17
JP2016535758A5 true JP2016535758A5 (enExample) 2017-09-28
JP6458270B2 JP6458270B2 (ja) 2019-01-30

Family

ID=52468825

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534884A Expired - Fee Related JP6458270B2 (ja) 2013-08-16 2014-08-18 置換されたヒドロキサム酸化合物
JP2018224004A Pending JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018224004A Pending JP2019077688A (ja) 2013-08-16 2018-11-29 置換されたヒドロキサム酸化合物

Country Status (6)

Country Link
US (1) US10647664B2 (enExample)
EP (1) EP3041354A4 (enExample)
JP (2) JP6458270B2 (enExample)
AU (1) AU2014306451B2 (enExample)
CA (1) CA2921427A1 (enExample)
WO (1) WO2015024010A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647664B2 (en) * 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
EP3143007B1 (en) 2014-05-16 2018-07-11 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
WO2017083434A1 (en) 2015-11-09 2017-05-18 Forge Therapeutics, Inc. Pyrone based compounds for treating bacterial infections
WO2017083431A2 (en) 2015-11-09 2017-05-18 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
EP3448375B1 (en) * 2016-04-25 2023-09-27 Duke University Benzoylglycine derivatives and methods of making and using same
WO2018115421A1 (en) * 2016-12-23 2018-06-28 Intervet International B.V. Compounds useful for treating a mannheimia haemolytica or histophilus somni infection
EP3621962A4 (en) 2017-05-10 2020-12-09 Forge Therapeutics, Inc. ANTIBACTERIAL COMPOUNDS
BR112020016270A2 (pt) * 2018-02-10 2020-12-15 Kbp Biosciences Co., Ltd. Composto atuando como antibióticos
CA3113226A1 (en) * 2018-09-20 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
US12617767B2 (en) 2019-07-17 2026-05-05 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
WO2022055880A1 (en) 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
CA3233328A1 (en) 2021-09-28 2023-04-06 Min Teng Lpxc inhibitors and uses thereof
US20260102415A1 (en) * 2022-10-05 2026-04-16 Duke University Compositions comprising prodrugs of hydroxamate-based compounds and methods of making and using same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JP2000344752A (ja) * 1999-04-01 2000-12-12 Sumitomo Pharmaceut Co Ltd 点眼剤
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
ATE510817T1 (de) * 2002-01-29 2011-06-15 Merck Serono Sa Substituierte methylenamidderivate als modulatoren von proteintyrosinphosphatasen (ptps)
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
AU2003267991B2 (en) 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
SG159388A1 (en) 2003-01-08 2010-03-30 Chiron Corp Antibacterial agents
US20050154022A1 (en) 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
AT502219B1 (de) 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
US7553864B2 (en) 2005-12-01 2009-06-30 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
JP2010502617A (ja) 2006-08-31 2010-01-28 シェーリング コーポレイション 抗菌物質として有用なヒダントイン誘導体
JP5227304B2 (ja) 2007-02-28 2013-07-03 大正製薬株式会社 新規なヒドロキサム酸誘導体
CA2934114A1 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
WO2009158369A1 (en) 2008-06-25 2009-12-30 Schering Corporation Synthesis and use of heterocyclic antibacterial agents
EP2315746A1 (en) 2008-08-04 2011-05-04 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011005355A1 (en) 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
PL2512474T3 (pl) 2009-12-16 2015-03-31 Pfizer N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne
SG184958A1 (en) * 2010-04-20 2012-11-29 Taisho Pharmaceutical Co Ltd Novel hydroxamic acid derivative
WO2012031298A2 (en) 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
JP6006609B2 (ja) * 2011-10-19 2016-10-12 大正製薬株式会社 新規なヒドロキサム酸誘導体を含有する医薬
EP2847168A1 (en) * 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
LT2975022T (lt) * 2013-03-15 2019-07-25 Fujifilm Toyama Chemical Co., Ltd. Naujas hidroksamo rūgšties darinys arba jo druska
US10647664B2 (en) * 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds

Similar Documents

Publication Publication Date Title
JP2012502946A5 (enExample)
ES2372020T3 (es) Heteroarilureas que contienen heteroátomos de nitrógeno como inhibidores de quinasa p38.
JP2021504443A5 (enExample)
JP2021532124A5 (enExample)
JP2020502047A5 (enExample)
JP2019506430A5 (enExample)
JP2016505619A5 (enExample)
JP2017526636A5 (enExample)
JP2013542937A5 (enExample)
JP2016525122A5 (enExample)
JP2007523155A5 (enExample)
JP2010540525A5 (enExample)
JP2007502804A5 (enExample)
JP2013510884A5 (enExample)
JP2009544602A5 (enExample)
JP2007525516A5 (enExample)
JP2015508749A5 (enExample)
JP2008505874A5 (enExample)
HRP20150049T1 (hr) Derivati oksazolil-metiletera kao agonisti alx-receptora
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
JP2017505293A5 (enExample)
JP2017513892A5 (enExample)
JP2017508795A5 (enExample)
JP2020521772A5 (enExample)